ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DRUG Bright Minds Biosciences Inc

1.05
-0.0425 (-3.89%)
Jun 15 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 7,729
Bid Price 1.01
Ask Price 1.64
News -
Day High 1.08

Low
0.93

52 Week Range

High
6.44

Day Low 0.99
Company Name Stock Ticker Symbol Market Type
Bright Minds Biosciences Inc DRUG NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0425 -3.89% 1.05 00:00:07
Open Price Low Price High Price Close Price Prev Close
1.08 0.99 1.08 1.05 1.0925
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
69 7,729 $ 1.04 $ 8,050 - 0.93 - 6.44
Last Trade Time Type Quantity Stock Price Currency
16:00:00 15 $ 1.03 USD

Bright Minds Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.69M 4.46M - 0 -7.37M -1.65 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Bright Minds Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No DRUG Message Board. Create One! See More Posts on DRUG Message Board See More Message Board Posts

Historical DRUG Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.091.180.991.1012,407-0.04-3.67%
1 Month1.111.280.991.1614,080-0.06-5.41%
3 Months1.221.450.931.1617,120-0.17-13.93%
6 Months1.402.390.931.5825,994-0.35-25.00%
1 Year2.856.440.933.68187,495-1.80-63.16%
3 Years44.7544.750.9310.361,419,673-43.70-97.65%
5 Years44.7544.750.9310.361,419,673-43.70-97.65%

Bright Minds Biosciences Description

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Your Recent History

Delayed Upgrade Clock